References
- AmbatiJAmbatiBKYooSHIanchulevSAdamisAPAge-related macular degeneration: etiology, pathogenesis, and therapeutic strategiesSurv Ophthalmol200348325729312745003
- BresslerNMBresslerSBFineSLAge-related macular degenerationSurv Ophthalmol19883263754132457955
- GuyerDRFineSLMaguireMGHawkinsBSOwensSLMurphyRPSubfoveal choroidal neovascular membranes in age-related macular degeneration. Visual prognosis in eyes with relatively good initial visual acuityArch Ophthalmol198610457027052423062
- GattoBCavalliMFrom proteins to nucleic acid-based drugs: the role of biotech in anti-VEGF therapyAnticancer Agents Med Chem20066428730116842232
- GaudreaultJFeiDRusitJSubocPShiuVPreclinical pharmacokinetics of Ranibizumab (rhuFabV2) after a single intravitreal administrationInvest Ophthalmol Vis Sci200546272673315671306
- RosenfeldPJBrownDMHeierJSRanibizumab for neovascular age-related macular degenerationN Engl J Med2006355141419143117021318
- RegilloCDBrownDMAbrahamPRandomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1Am J Ophthalmol2008145223924818222192
- ChangTSBresslerNMFineJTDolanCMWardJKlesertTRImproved vision-related function after ranibizumab treatment of neovascular age-related macular degeneration: results of a randomized clinical trialArch Ophthalmol2007125111460146917998507
- BhatnagarPSpaideRFTakahashiBSRanibizumab for treatment of choroidal neovascularization secondary to age-related macular degenerationRetina200727784685017891007
- BrownMMBrownGCBrownHCPeetJA value-based medicine analysis of ranibizumab for the treatment of subfoveal neovascular macular degenerationOphthalmology2008115610391045.e517976724
- AveryRLPieramiciDJRabenaMDCastellarinAANasirMAGiustMJIntravitreal bevacizumab (Avastin) for neovascular age-related macular degenerationOphthalmology20061133363372.e516458968
- RichRMRosenfeldPJPuliafitoCAShort-term safety and efficacy of intravitreal bevacizumab (Avastin) for neovascular age-related macular degenerationRetina200626549551116770255
- BashshurZFHaddadZASchakalAJaafarRFSaabMNoureddinBNIntravitreal bevacizumab for treatment of neovascular age-related macular degeneration: a one-year prospective studyAm J Ophthalmol2008145224925618067876
- BuysYMBevacizumab: the need for controlled studies to move forwardCan J Ophthalmol200742678918059506
- SinghRPKaiserPKRole of ranibizumab in management of macular degenerationIndian J Ophthalmol200755642142517951897
- MelamudAStinnettSFekratSTreatment of neovascular age-related macular degeneration with intravitreal bevacizumab: efficacy of three consecutive monthly injectionsAm J Ophthalmol20081461919518455144
- DevenyiRGEditorial: update on the modern management of wet age-related macular degenerationCan J Ophthalmol200641213313816767199
- KleinRMKleinRBAvastin versus Lucentis: ethical issues in treatment of age-related macular degenerationRetina20072791163116518046218
- StepienKRosenfeldPPuliafitoCComparison of intravitreal bevacizumab followed by ranibizumab for the treatment of neovascular age-related macular degenerationRetina20092981067107319696701
- LevineJMarcusISorensonJSpaideRCooneyMFreundKBMacular hemorrhage in neovascular age-related macular degeneration after stabilization with antiangiogenic therapyRetina20092981074107919734761
- KaragiannisDMitropoulosPLadasILarge subretinal haemorrhage following change from intravitreal bevacizumab to ranibizumabOphthalmologica2009223427928219390227
- BakriSJKitzmannASRetinal pigment epithelial tear after intravitreal ranibizumabAm J Ophthalmol2007143350550717317396
- ScupolaACoscasGSoubraneGBalestrazziENatural history of macular subretinal hemorrhage in age-related macular degenerationOphthalmologica19992132971029885385
- StifterEMichelsSPragerFIntravitreal bevacizumab therapy for neovascular age-related macular degeneration with large submacular hemorrhageAm J Ophthalmol2007144688689217916314
- Schmidt-ErfurthULaquaHSchlotzer-SchrehardUViestenzANaumannGOHistopathological changes following photodynamic therapy in human eyesArch Ophthalmol2002120683584412049594
- SchnurrbuschUEWeltKHornLCWiedemannPWolfSHistological findings of surgically excised choroidal neovascular membranes after photodynamic therapyBr J Ophthalmol20018591086109111520762
- KaempfSJohnenSSalzAKWeinbergerAWalterPThumannGEffects of bevacizumab (Avastin) on retinal cells in organotypic cultureInvest Ophthalmol Vis Sci20084973164317118344448
- BakriSJSnyderMRReidJMPulidoJSEzzatMKSinghRJPharmacokinetics of intravitreal ranibizumab (Lucentis)Ophthalmology2007114122179218218054637
- GaudreaultJFeiDBeyerJCPharmacokinetics and retinal distribution of ranibizumab, a humanized antibody fragment directed against VEGF-A, following intravitreal administration in rabbitsRetina20072791260126618046235
- LadasIDKaragiannisDARouvasAAKotsolisAILiotsouAVergadosISafety of repeat intravitreal injections of bevacizumab versus ranibizumab: our experience after 2,000 injectionsRetina200929331331819287287